InsidersTradesSigma
Follow the Eton Pharmaceuticals, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Eton Pharmaceuticals, Inc. has published 80 insider filings. Market capitalisation: €1.7bn. The latest transaction was reported on 31 August 2026 (Levée d'options). Among the most active insiders: Opaleye Management Inc.. The full history is accessible without an account.
80
Insider Decl.
n/a
Thresholds
€548,115
8 ops.
Buy Volume
€29m
40 ops.
Sell Volume
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,956 of 29,062 companies
42.0
score / 100
Value37
Quality48
FCF yld0.6%
Earn yld-0.3%
EV/EBITDA·
ROE36%
Gross mgn53%
Net mgn-5.8%
Debt/EBITDA9.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations80 total
12,500 shares@ US$7.31Common StockSEC:0001437749-26-029308:4
50,000 shares@ US$3.78Common StockSEC:0001437749-26-029308:0
36,387 shares@ US$58.64Common StockSEC:0001437749-26-029308:1
13,485 shares@ US$60.21Common StockSEC:0001437749-26-029308:2
128 shares@ US$61.77Common StockSEC:0001437749-26-029308:3
50,000 shares@ US$59.07060.17% mcap48.4% of flowCommonSEC144:0001974078-26-000335
50,000 shares@ US$3.780.011% mcap6.0% of flowCommon StockSEC:0001437749-26-029196:0
36,387 shares@ US$58.640.12% mcap67.9% of flowCommon StockSEC:0001437749-26-029196:1
13,485 shares@ US$60.210.045% mcap25.8% of flowCommon StockSEC:0001437749-26-029196:2
128 shares@ US$61.770.0004% mcap0.3% of flowCommon StockSEC:0001437749-26-029196:3
25,000 shares@ US$65.070.088% mcap22.4% of flowCommonSEC144:0001974078-26-000328
25,000 shares@ US$7.310.010% mcap3.2% of flowCommon StockSEC:0001437749-26-028846:0
25,000 shares@ US$65.070.090% mcap28.8% of flowCommon StockSEC:0001437749-26-028846:1
100,000 shares@ US$63.430.35% mcap26.2% of flowCommonSEC144:0001974078-26-000322
47,307 shares@ US$60.170.16% mcap15.8% of flowCommon StockSEC:0001437749-26-028651:1
7,342 shares@ US$62.120.025% mcap2.5% of flowCommon StockSEC:0001437749-26-028651:3
8,978 shares@ US$62.650.031% mcap3.2% of flowCommon StockSEC:0001437749-26-028651:0
36,373 shares@ US$61.110.12% mcap12.4% of flowCommon StockSEC:0001437749-26-028651:2
100,000 shares@ US$63.430.35% mcap53.8% of flowCommonSEC144:0001974078-26-000315
13,315 shares@ US$37.54310.028% mcap4.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033818:1
15,000 shares@ US$37.54310.032% mcap5.1% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033818:0
15,000 shares@ US$37.54310.032% mcap5.2% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033577:0
13,315 shares@ US$37.54310.028% mcap4.6% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033577:1
200,000 shares@ US$1.370.016% mcap5.1% of flowCommon StockSEC:0001437749-26-023570:1
27,500 sharesCommon StockSEC:0001437749-26-023570:0
25 of 80 declarations
关于 Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc.（股票代码：ETON）是一家在美国纳斯达克上市的美国专业制药公司。Eton 总部位于伊利诺伊州迪尔帕克，于2017年作为 Imprimis/Harrow Health 生态系统中的一个独立实体成立，最初专注于医院注射剂和罕见病疗法。其商业模式围绕收购、开发和商业化小众处方产品，通常利用 FDA 505(b)(2) 途径，以比传统从头开发项目更快的速度将差异化疗法推向市场。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1710340/000161577418012575/s114004_424b4.htm?utm_source=openai)) 如今，Eton 将自己定位为一家罕见病和超罕见病公司，其产品组合包括已上市产品、许可收入和后期开发资产。公司的已上市产品包括 ALKINDI SPRINKLE、INCRELEX、KHINDIVI、HEMANGEOL、GALZIN、CARGLUMIC ACID、BETAINE、NITISINONE CAPSULES、PKU GOLIKE 和 TYR GOLIKE。这种广度为 Eton 提供了商业基础，同时也支持了以管线驱动的增长故事。因此，公司的收入构成比纯研发型生物技术公司更加多元化，但仍集中在相对较少的一系列专业产品中。（[etonpharma.com](https://www.etonpharma.com/products/)) 从竞争角度来看，Eton 是一家小型股专家，而非广泛的制药平台。其优势在于专注、监管灵活性以及识别服务不足市场的能力，在新配方、重新上市或权利收购可以创造价值的领域。同时，公司面临着小众制药业务的典型风险：对有限数量产品的依赖、监管时机风险、商业执行风险以及定价/报销压力。Eton 当前的战略反映了产品收购、内部开发和选择性对外许可的结合，旨在建立一个持久的罕见病特许经营权。（[etonpharma.com](https://www.etonpharma.com/products/)) 近期发展表明了显著的势头。2025年，Eton 报告产品销售持续环比增长，将 GALZIN 纳入其自身的商业分销基础设施，提交了 ET-600 的新药申请（NDA），并将 INCRELEX 在美国以外的权利许可给 Esteve Pharmaceuticals。公司还强调了几项预期产品发布和额外的后期项目。其最新的年度报告确认公司仍设在伊利诺伊州迪尔帕克，并指出 Medicare 风险有限，因为 Eton 的产品中只有一小部分处方给 Medicare 患者。因此，对于法国、比利时和瑞士的投资者而言，ETON 最好被视为一家在纳斯达克上市的美国专业制药公司，专注于罕见病，商业足迹适中，并且其管线面向高价值的小众适应症。（[ir.etonpharma.com](https://ir.etonpharma.com/static-files/8bea9cbb-49a6-4242-8f74-af05c5036636))
